BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 15507929)

  • 21. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
    Mahajan NN
    Cancer; 2007 Dec; 110(12):2819; author reply 2819-20. PubMed ID: 17969078
    [No Abstract]   [Full Text] [Related]  

  • 22. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations.
    Haber D
    N Engl J Med; 2002 May; 346(21):1660-2. PubMed ID: 12024000
    [No Abstract]   [Full Text] [Related]  

  • 23. Hereditary ovarian cancer--assessing risk and prevention strategies.
    Pavelka JC; Li AJ; Karlan BY
    Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer.
    Michelsen TM; Dørum A; Dahl AA
    Gynecol Oncol; 2009 Apr; 113(1):128-33. PubMed ID: 19178933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylactic mastectomy and genetic testing: an update.
    Houshmand SL; Campbell CT; Briggs SE; McFadden AW; Al-Tweigeri T
    Oncol Nurs Forum; 2000; 27(10):1537-47; quiz 1548-9. PubMed ID: 11103373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.
    Biglia N; Mariani L; Ponzone R; Sismondi P
    Maturitas; 2008 Jun; 60(2):71-7. PubMed ID: 18472232
    [No Abstract]   [Full Text] [Related]  

  • 27. [Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation].
    Vodermaier A; Bauerfeind I; Untch M; Nestle-Krämling C
    Psychother Psychosom Med Psychol; 2006; 56(9-10):351-61. PubMed ID: 16804803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation.
    Finch A; Metcalfe KA; Chiang J; Elit L; McLaughlin J; Springate C; Esplen MJ; Demsky R; Murphy J; Rosen B; Narod SA
    Psychooncology; 2013 Jan; 22(1):212-9. PubMed ID: 21913283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hereditary breast cancer: treatment and prevention].
    Ejlertsen B; Gerdes AM
    Ugeskr Laeger; 2007 Sep; 169(36):2972-5. PubMed ID: 17953871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CA125 screening after risk-reducing salpingo-oophorectomy: are the titers too high, or is it all just too much?
    Bradford LS; Schorge JO
    Menopause; 2011 Feb; 18(2):123-4. PubMed ID: 21191312
    [No Abstract]   [Full Text] [Related]  

  • 31. Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
    Finch A; Metcalfe K; Lui J; Springate C; Demsky R; Armel S; Rosen B; Murphy J; Elit L; Sun P; Narod S
    Clin Genet; 2009 Mar; 75(3):220-4. PubMed ID: 19263514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
    Roukos DH; Briasoulis E
    Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer.
    Claes E; Evers-Kiebooms G; Decruyenaere M; Denayer L; Boogaerts A; Philippe K; Legius E
    Behav Med; 2005; 31(3):93-105. PubMed ID: 16252621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-port risk-reducing salpingo-oophorectomy with and without hysterectomy: surgical outcomes and learning curve analysis.
    Escobar PF; Starks DC; Fader AN; Barber M; Rojas-Espalliat L
    Gynecol Oncol; 2010 Oct; 119(1):43-7. PubMed ID: 20579712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
    Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
    JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Choices--and uncertainties--for women with BRCA mutations.
    Couzin J
    Science; 2003 Oct; 302(5645):592. PubMed ID: 14576419
    [No Abstract]   [Full Text] [Related]  

  • 37. Who is prone to high levels of distress after prophylactic mastectomy and/or salpingo-ovariectomy?
    Bresser PJ; Van Gool AR; Seynaeve C; Duivenvoorden HJ; Niermeijer MF; van Geel AN; Menke M; Klijn JG; Tibben A
    Ann Oncol; 2007 Oct; 18(10):1641-5. PubMed ID: 17660493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A survey of preventive measures among BRCA1 mutation carriers from Poland.
    Gronwald J; Byrski T; Huzarski T; Cybulski C; Stawicka M; Szwiec M; Debniak T; Tulman A; Sun P; Oszurek O; Lubinski J; Narod SA
    Clin Genet; 2007 Feb; 71(2):153-7. PubMed ID: 17250664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.
    Armstrong K; Schwartz JS; Randall T; Rubin SC; Weber B
    J Clin Oncol; 2004 Mar; 22(6):1045-54. PubMed ID: 14981106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers.
    Carcangiu ML; Radice P; Manoukian S; Spatti G; Gobbo M; Pensotti V; Crucianelli R; Pasini B
    Int J Gynecol Pathol; 2004 Jan; 23(1):35-40. PubMed ID: 14668548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.